FDA clears UniQure to submit Huntington's disease gene therapy for approval
The US Food and Drug Administration has reversed its earlier opposition, allowing UniQure to file its investigational RNA-interference treatment for Huntington's disease for regulatory review.
The US Food and Drug Administration (FDA) has resolved a dispute with Dutch biotechnology company UniQure and cleared the company to submit its Huntington's disease treatment, AMT-130, for formal regulatory approval, according to reporting by STAT News on 17 June 2026.
AMT-130 is an adeno-associated virus (AAV)-delivered RNA-interference therapy designed to reduce the production of mutant huntingtin protein — the toxic protein whose accumulation drives the progressive neurological damage characteristic of Huntington's disease. The FDA had previously raised objections that had blocked submission; the nature of those objections and the basis for the reversal were not fully disclosed in public reporting at the time of writing.
The development is notable for the Huntington's disease research and patient community because AMT-130 has been one of the most closely watched programmes in neurogenetic medicine. Earlier Phase I/II data generated interest, though the field has also seen setbacks with other huntingtin-lowering approaches from different developers.
Full details of the regulatory pathway, likely review timelines, and any conditions attached to the submission clearance are not yet available from public sources. The STAT News article is behind a paywall; this summary is based on the publicly available lede and headline. Genetic Current will update this cluster when further primary-source material becomes publicly accessible.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Huntington's disease is a rare inherited condition caused by a change in a single gene. It leads to progressive damage to the nervous system, affecting movement, thinking, and behaviour. There is currently no treatment that slows or stops the disease.
A biotechnology company called UniQure has been developing a treatment called AMT-130, which uses a biological delivery system to try to reduce the harmful protein that builds up in the brains of people with Huntington's disease. The US medicines regulator — the FDA — has now allowed UniQure to formally apply for the treatment to be approved. This does not mean the treatment is approved; it means the company can submit its evidence for regulators to assess.
Researchers and patient groups have been watching this programme closely. Further public information about timelines is expected as the regulatory process progresses.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-06-17STAT+: Following dispute with FDA, UniQure is cleared to submit Huntington's treatment for approval